Force of Nature: Tales of the Late Sir John Maddox



Loading...

By Kevin Davies

April 14, 2009 | COMMENTARY: Sir John Maddox, the editor emeritus of Nature, passed away on April 12, aged 83. During two stints as editor of Nature, the first from 1966-1973, the second from 1980-1995, Maddox restored the British journal’s reputation as perhaps the most prestigious science journal in the world.

Among many tributes, American science writer John Horgan called Maddox “hard-headed, scarily knowledgeable, hyper-articulate, unfailingly gracious even as he ripped you a new one.”

Born in Swansea, Wales, Maddox trained as a physicist but loved all flavors of science, sometimes to the point where it didn’t make perfect business sense. When Maddox resigned in 1973, Britain was paralyzed with the miner’s strike. Nature’s management abruptly scrapped his three-year experiment to publish three weekly issues — Nature, Nature Physical Sciences, and Nature New Biology.

During my brief stint in the magazine’s offices off Fleet Street in 1990, I caught fleeting glimpses of the man in action. One lunch time, he emerged from his smoke-filled corner office to introduce the staff to the Amazing James Randi. The brilliant American illusionist had accompanied Maddox to Paris to investigate the Benveniste homeopathy charade. I’d been wondering what Maddox was doing, traveling to France with a professional magician and a government bureaucrat to debunk a paper he had decided to publish. Randi proceeded to give us an impromptu magic show while we munched our sandwiches, instantly allaying any lingering doubts. 

Monday evenings, Maddox would settle in with a bottle of wine and a pack of cigarettes, and bash out the weekly editorial and the lead commentary. The subject matter could be anything from junk DNA to subatomic particles to nuclear disarmament. Occasionally he’d invite the staff to his Kensington townhouse for a party, but by the end of the evening, he’d be contentedly sitting in his dining room reading the newspaper, doubtless formulating his next editorial.

On one occasion in 1991, Maddox was perusing stacks of rejected manuscripts, pulling out papers where he might quibble with the editors’ decision. One rejected paper that perplexed him described the mapping of a gene for Lou Gehrig’s disease (ALS). “We are in the publishing business,” he chided the biology team, reminding us to keep in mind the importance of publishing papers of general interest. He called it “the David Niven Factor,” and not just because the British actor also died of ALS.

Maddox was supportive of plans to launch a Nature spin-off journal in 1992 in genetics, but characteristically he had strong views of how it should be run. Rather than be independent, he argued that Nature should simply hire a second genetics editor and review more papers. Management did not like that idea and Nature Genetics was created under independent editorial control. Well, almost… As we went to press with the inaugural issue, Maddox decided he should write the opening editorial himself. Maddox retired in 1995, and was knighted soon afterwards.

I last saw Maddox in Madrid in 2004, where he was a special guest at a cancer symposium hosted by the Spanish national cancer center (CNIO). He warmed to Iya Khalil, the co-founder of in silico company Gene Network Sciences, complementing her after her talk, saying that she had probably spoken twice as fast as any speaker he had ever heard -- while still being intelligible.

 

Maddox leaves a family of talented writers – his biographer wife Brenda, journalist daughter Bronwen (The Times), and novelist and Discover contributor son, Bruno – and many, many admiri

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

oracle_clinical
eClinical Visions - Clinical Trial Management: Enabling Operational Efficiency
Sponsored by Oracle

Read how contributors from Genzyme, Duke Clinical Research Institute, Accenture, Oracle Health Sciences and others address some of the most pertinent challenges facing the biopharmaceutical industry including... Globalization of clinical trials driven by the need to reduce costs and recruit participants; greater outsourcing; escalating regulatory demands; increased trial complexity; and post-marketing studies. Download this paper to gain new insight into:

  • Recent progress made in addressing these challenges
  • Expert opinion on clinical trial management systems (CTMS) for improving trial efficiencies
  • How to cut trial costs and enhance the productivity of trial participants


oracle_RDC
Remote Data Capture – Acquisition and Analysis
Sponsored by Oracle

Today nearly half of all clinical trials are conducted electronically, and rising! Electronic Data Capture (EDC) technology provides industry-wide opportunities, along with challenges, that are being addressed. In this informative report industry experts and users from Pfizer, PPD, C3i and Oracle Health Sciences discuss the impact of EDC and its newest zero footprint; online iteration.  It can used anywhere, world-wide, where the Internet is available while placing greater onus on global trial support. The critical focus of this new technology is that it must support the work of the person at the heart of the clinical trial system– the investigator. Download this report to learn more about:

  • Trends and Issues in an Electronic Clinical Data Management World
  • The New Remote Data Capture Paradigm 
  • Improving and Monitoring Clinical Data Management in the eClinical Age
  • Optimizing and Supporting Remote Data Capture


oracle_video
Technology Video Report: A Day in the Life with Remote Data Capture (Next-Gen EDC)
Sponsored by Oracle
See why Oracle Remote Data Capture (RDC) Onsite is the next generation in electronic data capture with its user-friendly method to collect, clean, review, and verify clinical trial data. Providing unprecedented performance with real-time data capture, Oracle RDC Onsite simplifies source data verification. With a clear, consistent view of study data across all sites, the benefits include reduced monitoring time, decreased queries and discrepancies, and less time to database lock.



Life Science Webcasts & Podcasts

Predict or Perish! Shaping the Practices of Clinical Trials
Decisionview webinarSponsored by:  DecisionView

Predictive Analytics are a key differentiator in running your clinical trials successfully through 2010 and beyond. They will help you to optimize your patient enrollment, reduce your clinical operations costs and minimize your financial liability in the clinical supply chain. In this session, you will:
• Learn what predictive analytics are and what they are not
• Understand why you need predictive analytics to run your clinical trials, and
• Explore how predictive analytics will shape the future of clinical trials

Download Now. 

 



More Podcasts

Job Openings

The University of Washington Department of Genome Sciences is seeking a LINUX SYSTEMS ENGINEERING MANAGER to lead a team in a diverse scientific computing environment that includes multiple HPC systems, petascale storage, and custom application servers. Apply online at UW Hires for req number 61505.  http://www.washington.edu/admin/hr/jobs/

Loading...

For reprints and/or copyright permission, please contact The YGS Group, 3650 West Market Street, York, PA;

(717) 505-9701 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.